MARATTO

article · Antimicrobial Agents and Chemotherapy

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases

202411 citationsOpen accessSouth Valley University

Abstract

The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were evaluated against several intrinsic and acquired class C β-lactamases. By contrast to vaborbactam and enmetazobactam, taniborbactam, xeruborbactam, and all diazabicyclooctanes demonstrated effective activities against most AmpC enzymes. Notably, durlobactam exhibited the most pronounced inhibitory effect. Interstingly, the chromosomal AmpC of <i>Acinetobacter baumannii</i> was the least sensitive enzyme to the newly developed β-lactamase inhibitors.

Research topics

  • Antibiotic Resistance in Bacteria
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Plant Pathogenic Bacteria Studies

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1128/aac.00775-24

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.